GlassScriptPhysician profile
Jay K Patel
NPI 1013034727
$26,504.78
in general payments reported to CMS, 2019-2025
39 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,081 · 2020: $2,173 · 2021: $1,379 · 2022: $15K · 2023: $3,756 · 2024: $1,331 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,870 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,166 · Consulting Fee: $25.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,870.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,166.00 |
| Consulting Fee | $25.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15,539.90 | 2021-2023 | |
| Horizon Therapeutics Plc | $1,698.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,411.48 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $1,066.28 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $998.38 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $871.54 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $708.88 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $577.71 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $457.05 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $390.83 | 2021-2025 | Benlysta, Shingrix, Arexvy |
| Ani Pharmaceuticals, INC. | $276.96 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $252.78 | 2019-2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $225.46 | 2019 | |
| Daiichi Sankyo INC. | $197.53 | 2019-2023 | Injectafer |
| Novo Nordisk INC | $190.17 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.